The core action of Epitalon capsule (also known as Epithalon or AEDG) does not directly target the blood coagulation system or platelet activation but rather reduces the risk of thrombosis through a multidimensional, systemic regulation of homeostasis. It promotes the repair of endothelial cells, enhances the activity of nitric oxide (NO) synthase, and increases the bioavailability of NO, thereby maintaining vasodilation, inhibiting vascular inflammatory responses, and reducing the expression of endothelial adhesion molecules. This effect helps preserve the integrity of the vascular wall and its anticoagulant phenotype, preventing the initiation of pathological thrombosis at its source.
The drug is not a conventional antithrombotic drug; instead, it indirectly reduces the overall risk of thrombosis by restoring physiological balance, delaying vascular aging, and enhancing the adaptive capacity of the entire system. Its effect represents a foundational and holistic approach to maintaining homeostasis, complementing the mechanisms of drugs that directly intervene in the coagulation cascade. This unique characteristic also gives it significant value in the fields of anti-aging and age-related cardiovascular risk prevention and control.
Our Products Form
Epitalon COA
Epitalon delays endothelial cell aging and reduces the risk of thrombosis
This is a synthetic tetrapeptide. Its ability to reduce thrombosis risk does not involve direct action on coagulation factors or the core pathways of platelet activation. Instead, it operates through indirect, multi-target, and multi-step regulation, building a stable anti-thrombotic environment by protecting vascular endothelial function, optimizing hemorheology, inhibiting oxidative stress and inflammation, and modulating neuroendocrine balance.
The vascular endothelium, as a crucial barrier, maintains integrity to prevent thrombosis. Endothelial damage exposes collagen, triggering platelet adhesion and coagulation. Epitalon capsule activates telomerase reverse transcriptase (TERT), extending endothelial cell telomeres to delay aging and apoptosis. This preserves endothelial proliferation and survival, reducing subendothelial matrix exposure and blocking thrombosis initiation. It also inhibits apoptosis pathways by downregulating pro-apoptotic proteins (e.g., Bax, Caspase-3) and upregulating anti-apoptotic Bcl-2, mitigating oxidative and metabolic stress to maintain vascular smoothness.
It boosts endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) bioavailability via PI3K/Akt pathway activation, enhancing NO synthesis while reducing its inactivation by ROS. Additionally, it upregulates prostacyclin (PGI₂) and thrombomodulin (TM) production. PGI₂ inhibits platelet aggregation and dilates vessels, synergizing with NO. TM binds thrombin to activate protein C, degrading factors Va and VIIIa, thereby suppressing coagulation amplification.
Reducing Whole Blood Viscosity and Plasma Viscosity
- Decreasing Erythrocyte Aggregation: Under pathological conditions, erythrocytes tend to aggregate into "rouleaux" due to changes in surface charge, increasing blood flow resistance. It can modulate the phospholipid composition and charge distribution of erythrocyte membranes, reducing intercellular adhesion, dispersing erythrocyte aggregates, and lowering whole blood viscosity.
- Improving Erythrocyte Deformability: Erythrocyte deformability is crucial for their passage through capillaries. Aging or oxidative stress can lead to erythrocyte stiffening and reduced deformability. This protects erythrocyte membrane integrity through its antioxidant effects, maintaining their flexibility, ensuring smooth blood flow in microcirculation, and preventing stasis.
Inhibiting Excessive Platelet Activation and Aggregation.Platelet activation is a core step in thrombosis, driven by agonists such as ADP, thromboxane A₂ (TXA₂), and collagen. While Epitalon capsule does not directly block platelet receptors, it indirectly inhibits platelet activation through the following mechanisms:
- Reducing the generation of reactive oxygen species (ROS) within platelets, thereby inhibiting the release of pro-aggregatory mediators like ADP and TXA₂.
- Downregulating the expression of P-selectin on platelet surfaces, which reduces platelet adhesion and cross-linking with endothelial cells and leukocytes, preventing the formation of platelet-leukocyte aggregates (a key component of thrombi).
Oxidative stress and chronic inflammation are the common pathological bases leading to vascular endothelial damage, platelet activation, and coagulation activation. The two mutually reinforce each other, forming a vicious cycle of "inflammation–oxidative stress–thrombosis." It breaks this cycle through dual modulation.
It upregulates the activity of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT), enhancing the cell's ability to clear reactive oxygen species (ROS). ROS attack endothelial cell membrane lipids, proteins, and DNA, causing endothelial damage, while also directly activating platelets and coagulation factor X, promoting thrombus formation. Additionally, Epitalon reduces the production of lipid peroxidation products such as malondialdehyde (MDA), protecting the membrane integrity of vascular endothelial cells and erythrocytes and maintaining their normal function.
Epitalon inhibits the release of pro-inflammatory cytokines and reduces the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) in serum. These inflammatory factors directly damage endothelial cells, induce the expression of adhesion molecules (such as ICAM-1 and VCAM-1) on endothelial cells, promote leukocyte adhesion and infiltration, and exacerbate vascular wall inflammation. They also stimulate the liver to synthesize acute-phase response proteins (such as fibrinogen), increasing plasma viscosity and elevating the risk of thrombosis. Furthermore, it blocks the NF-κB signaling pathway. Nuclear factor kappa B (NF-κB) is a key transcription factor regulating the expression of inflammatory cytokines. This inhibits the activation of IκB kinase (IKK), reduces the degradation of IκB, and thereby blocks the nuclear translocation of NF-κB, suppressing the transcription of downstream pro-inflammatory genes and inhibiting inflammatory responses at their source.
Maintaining Coagulation: Epitalon Fibrinolysis System Steady State
It does not directly interfere with the core activation pathways of coagulation factors or platelets. Instead, it regulates the body's neuroendocrine rhythms and metabolic balance to maintain the dynamic stability of the coagulation and fibrinolytic systems at a holistic level, thereby reducing the risk of thrombosis. Its specific mechanisms of action are divided into the following three aspects:
1. Regulating Melatonin Secretion and Restoring Circadian Rhythms of Vascular Tone
The secretion rhythm of melatonin by the pineal gland is highly synchronized with the circadian cycle. Disruption of this rhythm can disturb the physiological fluctuations in vascular tone. Epitalon capsule directly stimulates the pineal gland to synthesize and secrete melatonin, correcting circadian rhythm imbalances. Its antithrombotic effects are manifested in two dimensions:
Melatonin itself possesses antioxidant and anti-inflammatory activities, which synergistically mitigate oxidative stress damage to the vascular endothelium, reducing the pathological basis for platelet adhesion.
Melatonin modulates the contractile function of vascular smooth muscle cells, alleviating abnormal excessive vascular contraction at night. Nighttime is a high-risk period for thrombotic events (such as myocardial infarction and cerebral infarction), primarily due to slowed blood flow and increased vascular tension at night, which predisposes to blood stasis and platelet aggregation. The rhythmic secretion of melatonin promotes vasodilation and accelerates nocturnal blood flow, thereby reducing the risk of thrombosis caused by blood stasis.
2. Enhancing the Balance of the Coagulation-Fibrinolytic System to Regulate Bidirectional Thrombus Formation and Dissolution
The dynamic balance between coagulation and fibrinolysis is crucial for maintaining blood fluidity. An imbalance in either direction can lead to thrombosis or bleeding tendencies. Epitalon constructs an antithrombotic internal environment through bidirectional regulation of this system:
Inhibiting Coagulation Cascade Activation
Preclinical studies have confirmed that it can reduce the activity of coagulation factors VIII and IX in plasma. Coagulation factors VIII and IX are core components of the intrinsic coagulation pathway. A decrease in their activity reduces the conversion of prothrombin to thrombin, suppressing the coagulation cascade at its source and lowering the likelihood of a hypercoagulable state.
Enhancing Endogenous Fibrinolytic Activity
It significantly downregulates the expression of plasminogen activator inhibitor-1 (PAI-1) while upregulating the level of tissue-type plasminogen activator (t-PA). t-PA is a key activator of plasminogen, promoting its conversion into active plasmin, while PAI-1 specifically inhibits t-PA function and impedes fibrinolysis. Through the synergistic action of "upregulating t-PA + downregulating PAI-1," Epitalon accelerates the degradation of fibrin in the body, preventing the formation and expansion of thrombi.
Vascular lipid deposition, driven by dyslipidemia, is the core pathological basis of atherosclerosis. The rupture of unstable atherosclerotic plaques is the primary trigger for acute thrombotic events. Epitalon exerts upstream regulatory effects on thrombosis by improving lipid metabolism profiles:
It lowers serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LDL-C is the key lipoprotein responsible for lipid infiltration into the vascular endothelium. A reduction in its levels decreases lipid deposition in the subendothelial layer of blood vessels, slowing the formation and progression of atherosclerotic plaques.
By inhibiting plaque progression, Epitalon capsule reduces the expansion of the lipid core and thinning of the fibrous cap within plaques, enhancing plaque stability and lowering the risk of plaque rupture. When a plaque ruptures, procoagulant substances within the plaque are exposed to the bloodstream, rapidly triggering platelet aggregation and activation of the coagulation cascade, leading to acute thrombosis. By maintaining plaque stability, it addresses the root cause, reducing the occurrence of acute thrombotic events.
Conclusion
In summary, as a synthetic tetrapeptide (amino acid sequence Ala-Glu-Asp-Gly, AEDG), this drug exerts diverse biological functions in maintaining the body's homeostasis through its multi-target, multi-step regulatory characteristics. These functions encompass delaying cellular aging, protecting the vascular endothelium, regulating neuroendocrine balance, and optimizing metabolic homeostasis, among others. Among its many beneficial effects, its role in reducing thrombosis risk stands out-it does not directly interfere with core pathways of coagulation or platelet activation. Instead, it constructs a comprehensive anti-thrombosis defense system by preserving vascular endothelial integrity, optimizing hemorheological properties, inhibiting oxidative stress and inflammatory responses, and maintaining the homeostasis of the coagulation-fibrinolytic system through indirect pathways. This offers a novel auxiliary intervention strategy for thrombosis prevention, particularly for age-related and endothelial damage-related thrombosis.
While current research on Epitalon still has certain limitations-such as the need to expand the scope of clinical evidence and further refine long-term safety data-ongoing advances in scientific technology will enable a deeper understanding of its mechanisms and broader application scenarios. In the future, supported by more large-scale, multi-center clinical studies,it is expected to achieve greater breakthroughs in the field of anti-thrombosis and even in broader domains such as anti-aging and chronic disease prevention, bringing new vitality and possibilities to human health protection.
Hot Tags: epitalon capsule, China epitalon capsule manufacturers, suppliers, Botulinum Toxin Injection 100iu, Nad Capsule, Nad Peptide Injection, Nad Tablet, BPC 157 Peptide Cream, BPC 157 Peptide Capsules
